Chemotherapy in the Treatment and Control of Leishmaniasis

Advances in Parasitology

Volumn 61, Issue , 2006, Pages 223-274

  Alvar, Jorge ^a   Croft, Simon ^b   Olliaro, Piero ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; IMIQUIMOD; LIVER ENZYME; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ARTHRALGIA; BACKACHE; BONE PAIN; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; ENZYME BLOOD LEVEL; FEVER; HEART ARREST; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; INFECTION CONTROL; LEISHMANIASIS; METHEMOGLOBINEMIA; MYALGIA; MYOCARDITIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; RIGOR; SHOCK; SIDE EFFECT; VOMITING;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; DRUG RESISTANCE; FEMALE; HEALTH POLICY; HIV INFECTIONS; HUMANS; LEISHMANIASIS; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC;

EID: 33646823616     PISSN: 0065308X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-308X(05)61006-8     Document Type: Review

References (145)

1. Abdo M.G., Elamin W.M., Khalil E.A., and Mukhtar M.M. Antimony-resistant Leishmania donovani in eastern Sudan: incidence and in vitro correlation. East Mediterranean Health Journal 9 (2003) 837-843
2. Aggarwal P., and Wali J.P. Profile of kala-azar in north India. Asia Pacific Journal of Public Health 5 (1991) 90-93
3. Ahluwalia I.B., Bern C., Wagatsuma Y., Costa C., Chowdhury R., Ali M., Amann J., Haque R., Breiman R., and Maguire J.H. Visceral leishmaniasis: consequences to women in a Bangladeshi community. Journal of Women's Health (Larchmt) 13 (2004) 360-364
4. Allen S., and Neal R.A. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Hart D.T. (Ed). Leishmaniasis (1989), Plenum Press, New York
5. Alvar J., Canavate C., Gutierrez-Solar B., Jimenez M., Laguna F., López-Vélez R., Molina R., and Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews 10 (1997) 298-319
6. Alvar J., Canavate C., Molina R., Moreno J., and Nieto J. Canine leishmaniasis. Advances in Parasitology 57 (2004) 1-88
7. Alvar J., Molina R., San Andres M., Tesouro M., Nieto J., Vitutia M., Gonzalez F., San Andres M.D., Boggio J., Rodriguez F., Saïnz A., and Escacena C. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Annals of Tropical Medicine and Parasitology 88 (1994) 371-378
8. Amato V.S., Rabello A., Rotondo-Silva A., Kono A., Maldonado T.P., Alves I.C., Floeter-Winter L.M., Neto V.A., and Shikanai-Yasuda M.A. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Tropica 92 (2004) 127-132
9. Arevalo I., Ward B., Miller R., Meng T.C., Najar E., Alvarez E., Matlashewski G., and Llanos-Cuentas A. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clinical Infectious Disease 33 (2001) 1847-1851
10. Ashford R.W. The leishmaniases as emerging and reemerging zoonoses. International Journal for Parasitology 30 (2000) 1269-1281
11. Ashford R.W., Desjeux P., and de Raadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitology Today 8 (1992) 104-105
12. Attar Z.J., Chance M.L., El-Safi S., Carney J., Azazy A., El-Hadi M., Dourado C., and Hommel M. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Tropica 78 (2001) 11-16
13. Badaro R., Benson D., Eulalio M.C., Freire M., Cunha S., Netto E.M., Pedral-Sampaio D., Madureira C., Burns J.M., Houghton R.L., David J.R., and Reed S.G. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. Journal of Infectious Disease 173 (1996) 758-761
14. Ben Salah, A., Ben Alaya, N., Mokni, M., Morizot, G., Lehnert, E., doughty, S., Grögl, M., and Buffet, P.A. (2005b). Determining treatment efficacy in cutaneous leishmaniasis: an optimized clinical score based on both ulceration and induration outcomes. Abstract Book, Third World Congress on Leishmaniosis, 10-15 April, Sicily.
15. Ben Salah, A., Buffet, P.A., Louzir, H., Morizot, G., Zaâtour, A., Ben Alaya, N., Bel Hajhmida, N., Elahmadi, S., Chlif, S., Lehnert, E., Doughty, S., Dellagi, K., and Grögl, M. (2005a). WR279396 an efficient non toxic topical treatment of old world cutaneous leishmaniasis. Abstract Book, Third World Congress on Leishmaniosis, 10-15 April, Sicily, Italy.
16. Berenguer J., Cosin J., Miralles P., López J.C., and Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14 (2000) 2946-2948
17. Berhe N., Wolday D., Hailu A., Abraham Y., Ali A., Gebre-Michael T., Desjeux P., Sonnerborg A., Akuffo H., and Britton S. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 13 (1999) 1921-1925
18. Berman J.D., Badaro R., Thakur C.P., Wasunna K.M., Behbehani K., Davidson R., Kuzoe F., Pang L., Weerasuriya K., and Bryceson A.D. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of the World Health Organization 76 (1998) 25-32
19. Berman J.D., Chulay J.D., Hendricks L.D., and Oster C.N. Susceptibility of clinically sensitive and resistant Leishmania to pentavalent antimony in vitro. American Journal of Tropical Medicine and Hygiene 31 (1982) 459-465
20. Bodhe P.V., Kotwani R.N., Kirodian B.G., Pathare A.V., Pandey A.K., Thakur C.P., and Kshirsagar N.A. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 93 (1999) 314-318
21. Boelaert M., Lynen L., Desjeux P., and Van der Stuyft P. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis. Bulletin of the World Health Organization 77 (1999) 667-674
22. Boelaert M., Rijal S., Regmi S., Singh R., Karki B., Jacquet D., Chappuis F., Campino L., Desjeux P., Le Ray D., Koirala S., and Van der Stuyft P. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene 70 (2004) 72-77
23. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine & International Health 6 (2001) 928-934
24. Buates S., and Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. Journal of Infectious Disease 179 (1999) 1485-1494
25. Chunge C.N., Gachihi G., Muigai R., Wasunna K., Rashid J.R., Chulay J.D., Anabwani G., Oster C.N., and Bryceson A.D. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Transactions of the Royal Society of Tropical Medicine and Hygiene 79 (1985) 715-718
26. Chunge C.N., Owate J., Pamba H.O., and Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Transactions of the Royal Society of Tropical Medicine and Hygiene 84 (1990) 221-225
27. Coelho A.C., Beverley S.M., and Cotrim P.C. Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Molecular and Biochemical Parasitology 130 (2003) 83-90
28. Convit J., Castellanos P.L., Ulrich M., Castes M., Rondon A., Pinardi M.E., Rodriquez N., Bloom B.R., Formica S., Valecillos L., et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. Journal of Infectious Disease 160 (1989) 104-115
29. Convit J., Ulrich M., Zerpa O., Borges R., Aranzazu N., Valera M., Villarroel H., Zapata Z., and Tomedes I. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Transactions of the Royal Society of Tropical Medicine and Hygiene 97 (2003) 469-472
30. Copeland H.W., Arana B.A., and Navin T.R. Comparison of active and passive case detection of cutaneous leishmaniasis in Guatemala. American Journal of Tropical Medicine and Hygiene 43 (1990) 257-259
31. Cotrim P.C., Garrity L.K., and Beverley S.M. Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection. Journal of Biological Chemistry 274 (1999) 37723-37730
32. Croft, S.L., and Brun, R. (2003). in vitro and in vivo models for the identification and evaluation of drugs active against Trypanosoma and Leishmania. In: Drugs Against Parasitic Diseases: R&D Methodologies and Issues (A.H. Fairlamb, R. Ridley, and H. Vial, eds), UNDP/World Bank/ WHO Special Program for Research and Training in Tropical Diseases (TDR, Geneva), pp. 165-173.
33. Croft S.L., and Coombs G.H. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology 19 (2003) 502-508
34. Croft S.L., Neal R.A., Pendergast W., and Chan J.H. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochemical Pharmacology 36 (1987) 2633-2636
35. Croft S.L., Snowdon D., and Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Journal of Antimicrobial Chemotherapy 38 (1996) 1041-1047
36. Croft S.L., and Yardley V. Chemotherapy of leishmaniasis. Current Pharmaceutical Design 8 (2002) 319-342
37. Cruz, I., Moreno, J., Cañavate, C., Desjeux, P. and Alvar, J. (in press). Leishmania/HIV co-infections in the second decade. Indian Journal of Medical Research.
38. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., Pempinello R., Scott S., Raimondi F., Cascio A., Prestileo T., Caldeira L., Wilkinson R.J., and Bryceson A.D.M. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Quarterly Journal of Medicine 87 (1994) 75-81
39. de la Rosa R., Pineda J.A., Delgado J., Macias J., Morillas F., Mira J.A., Sánchez-Quijano A., Leal M., and Lissen E. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. Journal of Clinical Microbiology 40 (2002) 762-767
40. Dereure J., Duong Thanh H., Lavabre-Bertrand T., Cartron G., Bastides F., Richard-Lenoble D., and Dedet J.P. Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. Journal of Infection 47 (2003) 77-81
41. Desjeux P. Leishmaniasis. Public health aspects and control. Clinics in Dermatology 14 (1996) 417-423
42. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene 95 (2001) 239-243
43. Desjeux P. Leishmaniasis: current situation and new perspectives. Comparative Immunology Microbiology and Infectious Diseases 27 (2004) 305-318
44. Desjeux P., and Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Annals of Tropical Medicine and Parasitology 97 supplement 1 (2003) 3-15
45. Dietze R., Carvalho S.F., Valli L.C., Berman J., Brewer T., Milhous W., Sánchez J., Schuster B., and Grogl M. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. American Journal of Tropical Medicine and Hygiene 65 (2001) 685-689
46. Dube A., Singh N., Sundar S., and Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitology Research 96 (2005) 216-223
47. Elnaiem D.A., Hassan H.K., and Ward R.D. Associations of Phlebotomus orientalis and other sandflies with vegetation types in the eastern Sudan focus of kala-azar. Medical and Veterinary Entomology 13 (1999) 198-203
48. El-On J., Jacobs G.P., Witztum E., and Greenblatt C.L. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrobial Agents and Chemotherapy 26 (1984) 745-751
49. El-On J., Halevy S., Grunwald M.H., and Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. Journal of the American Academy of Dermatology 27 (1992) 227-231
50. El-Safi S.H., and Evans D.A. A comparison of the direct agglutination test and enzyme-linked immunosorbent assay in the sero-diagnosis of leishmaniasis in the Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene 83 (1989) 334-337
51. Eltoum I.A., Zijlstra E.E., Ali M.S., Ghalib H.W., Satti M.M., Eltoum B., and el-Hassan A.M. Congenital kala-azar and leishmaniasis in the placenta. American Journal of Tropical Medicine and Hygiene 46 (1992) 57-62
52. Ephros M., Waldman E., and Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrobial Agents and Chemotherapy 41 (1997) 1064-1068
53. Escobar P., Yardley V., and Croft S.L. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient SCID mice. Antimicrobial Agents and Chemotherapy 45 (2001) 1872-1875
54. Evans T.G., Teixeira M.J., McAuliffe I.T., Vasconcelos I., Vasconcelos A.W., Sousa Ade A., Lima J.W., and Pearson R.D. Epidemiology of visceral leishmaniasis in northeast Brazil. Journal of Infectious Disease 166 (1992) 1124-1132
55. Fukui H., Koike T., Nakagawa T., Saheki A., Sonoke S., Tomii Y., and Seki J. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. International Journal of Pharmaceutics 267 (2003) 101-112
56. Gama M.E., Costa J.M., Gomes C.M., and Corbett C.E. Subclinical form of the American visceral leishmaniasis. Memórias do Instituto Oswaldo Cruz 99 (2004) 889-893
57. Garnier T., and Croft S.L. Topical treatment for cutaneous leishmaniasis. Current Opinion in Investigative Drugs 3 (2002) 538-544
58. Gradoni L., Gramiccia M., and Scalone A. Visceral leishmaniasis treatment, Italy. Emerging Infectious Disease 9 (2003) 1617-1620
59. Gramiccia M., Gradoni L., and Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Annals of Tropical Medicine and Parasitology 86 (1992) 613-620
60. Griekspoor A., Sondorp E., and Vos T. Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan. Health Policy and Planning 14 (1999) 70-76
61. Grogl M., Thomason T.N., and Franke E.D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. American Journal of Tropical Medicine and Hygiene 47 (1992) 117-126
62. Guerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., Wasunna M.K., and Bryceson A.D. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Disease 2 (2002) 494-501
63. Guiguemde R.T., Sawadogo O.S., Bories C., Traore K.L., Nezien D., Nikiema L., Pratlong F., Marty P., Houin R., and Deniau M. Leishmania major and HIV co-infection in Burkina Faso. Transactions of the Royal Society of Tropical Medicine and Hygiene 97 (2003) 168-169
64. Harrison L.H., Naidu T.G., Drew J.S., de Alencar J.E., and Pearson R.D. Reciprocal relationships between undernutrition and the parasitic disease visceral leishmaniasis. Review of Infectious Disease 8 (1986) 447-453
65. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
66. Ibrahim M.E., Hag-Ali M., el-Hassan A.M., Theander T.G., and Kharazmi A. Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing. Parasitology Research 80 (1994) 569-574
67. Iraji F., and Sadeghinia A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran. Annals of Tropical Medicine and Parasitology 99 (2005) 3-9
68. Jha T.K., Olliaro P., Thakur C.P., Kanyok T.P., Singhania B.L., Singh I.J., Singh N.K., Akhoury S., and Jha S. Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. British Medical Journal 316 (1998) 1200-1205
69. Jha, T.K., Sundar, S., Bhattacharya, S.K., Sinha, P.K., and Thakur, C.P. (2005a). Paromomycin as a new cure for visceral leishmaniasis: preliminary results of a Phase III randomized controlled trial of efficacy and safety. Abstract Book, Third World Congress on Leishmaniasis, 10-15 April 2005, Sicily, Italy.
70. Jha T.K., Sundar S., Thakur C.P., Sabin A.J., Horton J., and Felton J.M. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. American Journal of Tropical Medicine and Hygiene 73 (2005) 1005-1111
71. Kafetzis D.A. An overview of paediatric leishmaniasis. Journal of Postgraduate Medicine 49 (2003) 31-38
72. Kuhlencord A., Maniera T., Eibl H., and Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrobial Agents and Chemotherapy 36 (1992) 1630-1634
73. Kwong E.H., Ramaswamy M., Bauer E.A., Hartsel S.C., and Wasan K.M. Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits. Antimicrobial Agents and Chemotherapy 45 (2001) 2060-2063
74. Laguna F., López-Vélez R., Pulido F., Salas A., Torre-Cisneros J., Torres E., Medrano F.J., Sanz J., Pico G., Gómez-Rodrigo J., Pasquau J., and Alvar J. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. AIDS 13 (1999) 1063-1069
75. Laguna F., Videla S., Jiménez-Mejias M.E., Sirera G., Torre-Cisneros J., Ribera E., Prados D., Clotet B., Sust M., López-Vélez R., and Alvar J. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. Journal of Antimicrobial Chemotherapy 52 (2003) 464-468
76. le Fichoux Y., Quaranta J.F., Aufeuvre J.P., Lelievre A., Marty P., Suffia I., Rousseau D., and Kubar J. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. Journal of Clinical Microbiology 37 (1999) 1953-1957
77. Lira R., Sundar S., Makharia A., Kenney R., Gam A., Saraiva E., and Sacks D. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. Journal of Infectious Disease 180 (1999) 564-567
78. López-Vélez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Annals of Tropical Medicine and Parasitology 97 supplement 1 (2003) 143-147
79. López-Vélez R., Perez-Molina J.A., Guerrero A., Baquero F., Villarrubia J., Escribano L., Bellas C., Pérez-Corral F., and Alvar J. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. American Journal of Tropical Medicine and Hygiene 58 (1998) 436-443
80. López-Vélez R., Videla S., Márquez M., Boix V., Jiménez-Mejias M.E., Gorgolas M., Arribas J.R., Salas A., Laguna F., Sust M., Cãnavate C., and Alvar J. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. Journal of Antimicrobial Chemotherapy 53 (2004) 540-543
81. Lyons S., Veeken H., and Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Tropical Medicine & International Health 8 (2003) 733-739
82. Maarouf M., Adeline M.T., Solignac M., Vautrin D., and Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 5 (1998) 167-173
83. McCormick A.W., Whitney C.G., Farley M.M., Lynfield R., Harrison L.H., Bennett N.M., Schaffner W., Reingold A., Hadler J., Cieslak P., Samore M.H., and Lipsitch M. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nature Medicine 9 (2003) 424-430
84. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Disease 28 (1999) 42-48 (discussion 49-51)
85. Mira J.A., Corzo J.E., Rivero A., Macias J., de Leon F.L., Torre-Cisneros J., Gomez-Mateos J., Jurado R., and Pineda J.A. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. American Journal of Tropical Medicine and Hygiene 70 (2004) 298-301
86. Momeni A.Z., and Aminjavaheri M. Treatment of recurrent cutaneous leishmaniasis. International Journal of Dermatology 34 (1995) 129-133
87. Moreno J., Nieto J., Chamizo C., Gonzalez F., Blanco F., Barker D.C., and Alvar J. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Veterinary Immunology and Immunopathology 71 (1999) 181-195
88. Murray H.W. Treatment of visceral leishmaniasis in 2004. American Journal of Tropical Medicine and Hygiene 71 (2004) 787-794
89. Murray C.J.L., and Lopez A. Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for over 200 Conditions (1996), Harvard School of Public Health on behalf of World Health Organization and World Bank (Global Burden of Disease and Injury Series), Boston, MA
90. Musa A.M., Khalil E.A., Mahgoub F.A., Hamad S., Elkadaru A.M., and el-Hassan A.M. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Annals of Tropical Medicine and Parasitology 99 (2005) 563-569
91. Navin T.R., Arana B.A., Arana F.E., Berman J.D., and Chajon J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. Journal of Infectious Disease 165 (1992) 528-534
92. Neal R.A., Allen S., McCoy N., Olliaro P., and Croft S.L. The sensitivity of Leishmania species to aminosidine. Journal of Antimicrobial Chemotherapy 35 (1995) 577-584
93. Neal R.A., Croft S.L., and Nelson D.J. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026. Transactions of the Royal Society of Tropical Medicine and Hygiene 79 (1985) 122-128
94. Olliaro P.L., Guerin P.J., Gerstl S., Haaskjold A.A., Rottingen J.A., and Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infectious Disease 5 (2005) 763-774
95. Pagliano P., Carannante N., Rossi M., Gramiccia M., Gradoni L., Faella F.S., and Gaeta G.B. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. Journal of Antimicrobial Chemotherapy 55 (2005) 229-233
96. Pagliano P., Rossi M., Rescigno C., Altieri S., Coppola M.G., Gramiccia M., Scalone A., Gradoni L., and Faella F. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). Journal of Antimicrobial Chemotherapy 52 (2003) 264-268
97. Paumgartten F.J., and Chahoud I. Embryotoxicity of meglumine antimoniate in the rat. Reproductive Toxicology 15 (2001) 327-331
98. Pérez-Victoria F.J., Gamarro F., Ouellette M., and Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. Journal of Biological Chemistry 278 (2003) 49965-49971
99. Petit C., Yardley V., Gaboriau F., Bolard J., and Croft S.L. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrobial Agents and Chemotherapy 43 (1999) 390-392
100. Pintado V., and López-Vélez R. Visceral leishmaniasis associated with human immunodeficiency virus infection. Enfermedades Infecciosas y Microbiologia Clinica 19 (2001) 353-357
101. Pintado V., Martín-Rabadán P., Rivera M.L., Moreno S., and Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80 (2001) 54-73
102. Rabello A., Orsini M., and Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Annals of Tropical Medicine and Parasitology 97 supplement 1 (2003) 17-28
103. Reithinger R., Mohsen M., Wahid M., Bismullah M., Quinnell R.J., Davies C.R., Kolaczinski J., and David J.R. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clinical Infectious Disease 40 (2005) 1148-1155
104. Ribera E., Ocaña I., de Otero J., Cortés E., Gasser I., and Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. American Journal of Medicine 100 (1996) 496-501
105. Rijal S., Chappuis F., Singh R., Boelaert M., Loutan L., and Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Transactions of the Royal Society of Tropical Medicine and Hygiene 97 (2003) 597-598
106. Ritmeijer K., Veeken H., Melaku Y., Leal G., Amsalu R., Seaman J., and Davidson R.N. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Transactions of the Royal Society of Tropical Medicine and Hygiene 95 (2001) 668-672
107. Russo R., Nigro L.C., Minniti S., Montineri A., Gradoni L., Caldeira L., and Davidson R.N. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). Journal of Infection 32 (1996) 133-137
108. Sampaio R.N., Salaro C.P., Resende P., and de Paula C.D. American cutaneous leishmaniasis associated with HIV/AIDS: report of four clinical cases. Revista da Sociedade Brasileira de Medicina Tropical 35 (2002) 651-654
109. Sarkari B., Chance M., and Hommel M. Antigenuria in visceral leishmaniasis: detection and partial characterisation of a carbohydrate antigen. Acta Tropica 82 (2002) 339-348
110. Seeberger J., Daoud S., and Pammer J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. International Journal of Dermatology 42 (2003) 576-579
111. Seifert K., and Croft S.L. In vitro and in vivo interactions between miltefosine and anti-leishmanial drugs. Antimicrobial Agents and Chemotherapy 50 (2006) 73-79
112. Seifert K., Matu S., Pérez-Victoria F.J., Castanys S., Gamarro F., and Croft S.L. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). International Journal of Antimicrobial Agents 22 (2003) 380-387
113. Sereno D., and Lemesre J.L. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrobial Agents and Chemotherapy 41 (1997) 972-976
114. Sharma, D., Bern, C., Varghese, B., Chowdhury, R., Haque, R., Ali, M., Amann, J., Ahluwalia, I.B., Wagatsuma, Y., Breiman, R., Maguire, J.H., and McFarland, D.A. (in press). The economic impact of visceral leishmaniasis on households in Bangladesh. Tropical Medicine & International Health.
115. Sherwood J.A., Gachihi G.S., Muigai R.K., Skillman D.R., Mugo M., Rashid J.R., Wasunna K.M., Were J.B., Kasili S.K., and Mbugua J.M. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clinical Infectious Disease 19 (1994) 1034-1039
116. Sindermann H., Engel K.R., Fischer C., and Bommer W. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clinical Infectious Disease 39 (2004) 1520-1523
117. Sinha P.K., Rabidas V.N., Pandey K., Verma N., Gupta A.K., Ranjan A., Das P., and Bhattacharya S.K. Visceral leishmaniasis and HIV coinfection in Bihar, India. Journal of Acquired Immune Deficiency Syndromes 32 (2003) 115-116
118. Soriano V., Dona C., Rodríguez-Rosado R., Barreiro P., and Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14 (2000) 383-386
119. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Díaz A., Luz M., Gutiérrez P., Arboleda M., Berman J.D., Junge K., Engel J., and Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Disease 38 (2004) 1266-1272
120. Soto J.M., Toledo J.T., Gutíerrez P., Arboleda M., Nicholls R.S., Padilla J.R., Berman J.D., English C.K., and Grogl M. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. American Journal of Tropical Medicine and Hygiene 66 (2002) 147-151
121. Sundar S. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine & International Health 6 (2001) 849-854
122. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., and Berman J. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine 347 (2002) 1739-1746
123. Sundar S., Mehta H., Suresh A.V., Singh S.P., Rai M., and Murray H.W. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clinical Infectious Disease 38 (2004) 377-383
124. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., Kumar P.C., and Murray H.W. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Disease 31 (2000) 1104-1107
125. Sundar S., and Murray H.W. Availability of miltefosine for the treatment of kala-azar in India. Bulletin of the World Health Organization 83 (2005) 394-395
126. Sundar S., Rosenkaimer F., Lesser M.L., and Murray H.W. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. Journal of Infectious Diseases 171 (1995) 992-996
127. Sundar S., Singh V.P., Sharma S., Makharia M.K., and Murray H.W. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Disease 176 (1997) 1117-1119
128. Sundar S., Sinha P.R., Agrawal N.K., Srivastava R., Rainey P.M., Berman J.D., Murray H.W., and Singh V.P. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. American Journal of Tropical Medicine and Hygiene 59 (1998) 139-143
129. Teklemariam S., Hiwot A.G., Frommel D., Miko T.L., Ganlov G., and Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Transactions of the Royal Society of Tropical Medicine and Hygiene 88 (1994) 334-339
130. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Messick C., and Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Transactions of the Royal Society of Tropical Medicine and Hygiene 94 (2000) 432-433
131. Thakur C.P., Kanyok T.P., Pandey A.K., Sinha G.P., Zaniewski A.E., Houlihan H.H., and Olliaro P. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 94 (2000) 429-431
132. Thakur C.P., and Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian Journal of Medical Research 91 (1990) 144-148
133. Thakur C.P., Narain S., Kumar N., Hassan S.M., Jha D.K., and Kumar A. Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Annals of Tropical Medicine and Parasitology 91 (1997) 611-616
134. Thakur C.P., and Narayan S. A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis. Annals of Tropical Medicine and Parasitology 98 (2004) 129-138
135. Thakur C.P., Narayan S., and Ranjan A. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian Journal of Medical Research 120 (2004) 166-172
136. Thakur C.P., Sinha G.P., Pandey A.K., Barat D., and Sinha P.K. Amphotericin B in resistant kala-azar in Bihar. National Medical Journal of India 6 (1993) 57-60
137. Thakur C.P., Sinha G.P., Pandey A.K., Kumar N., Kumar P., Hassan S.M., Narain S., and Roy R.K. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Annals of Tropical Medicine and Parasitology 92 (1998) 561-569
138. Thakur C.P., Sinha G.P., Sharma V., Pandey A.K., Kumar M., and Verma B.B. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian Journal Medical Research 97 (1993) 170-175
139. UNAIDS (2005). AIDS Epidemic Update 2005 (www.unaids.org).
140. Wasunna M.K., Rashid J.R., Mbui J., Kirigi G., Kinoti D., Lodenyo H., Felton J.M., Sabin A.J., and Horton J. A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. American Journal of Tropical Medicine and Hygiene 73 (2005) 871-876
141. White N.J., and Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proceedings of the Royal Society of London Series B 270 (2002) 545-554
142. Yamey G., and Torreele E. The world's most neglected diseases. British Medical Journal 325 (2002) 176-177
143. Yardley V., Croft S.L., De Doncker S., Dujardin J.C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., and Chappuis F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. American Journal of Tropical Medicine and Hygiene 73 (2005) 272-275
144. Zijlstra E.E., and el-Hassan A.M. Leishmaniasis in Sudan Post kala-azar dermal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95 supplement 1 (2001) S59-S76
145. Zvulunov A., Cagnano E., Frankenburg S., Barenholz Y., and Vardy D. Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B. Pediatric Infectious Disease Journal 22 (2003) 567-569